Rabies lyssavirus
| ABMA | RABV | Prevents endosomal fusion/maturation | Preclinical | — | Human GTPase | |
| Amodiaquine | RABV | Methyltransferase inhibitor | Preclinical | — | Human HNMT | |
| Clofazimine | RABV | Non-nucleoside RT inhibitor | Preclinical | — | Viral RNA pol | |
| DABMA | RABV | Prevents endosomal fusion/maturation | Preclinical | — | Human GTPase | |
| Emetine | RABV | — | Preclinical | — | Human ribosome | |
| Favipiravir | RABV | Viral RNA polymerase inhibitor | Approved (other) | Japan | Viral RNA pol | |
| Inosine (Inosine pranobex) | RABV | Stimulates cell-mediated immune response | Preclinical | — | Viral RNA pol | |
| Niclosamide | RABV | — | Preclinical | — | Human (multiple) | |
| Raloxifene | RABV | Selective estrogen receptor modulator | Preclinical | — | Human (multiple) | |
| Reserpine | RABV | Unknown | Preclinical | — | Unknown | |
| Ribavirin | RABV | Nucleoside inhibitor; Guanosine (ribonucleic) analog | Approved (other) | Japan | Viral RNA pol | |
| Sorafenib | RABV | B-Raf; FGFR-1; VEGFR-2 & -3; PDGFR-beta; KIT; and FLT3 inhibitor | Preclinical | — | Human PTK | |
| Vidarabine | RABV | Viral DNA synthesis inhibitor | Approved (other) | Japan | Viral RNA pol |